Hanmi’s Eppe Undercuts Wegovy and Mounjaro as Korea’s First Homegrown GLP-1 Obesity Drug
Hanmi Pharmaceutical’s Eppe (efpeglenatide) became South Korea’s first domestically developed GLP-1 obesity drug to reach clinics, arriving at selected sites on Oct. 29, 2025, roughly three weeks after the Ministry of Food and Drug Safety approved it, with a first-four-week supply price of 129,800 won (about $96.6) — less than half the 278,066 won starter price of Eli Lilly’s Mounjaro and roughly 40 percent below Novo Nordisk’s Wegovy at about 216,000 won. The launch tests whether a homegrown GLP-1 peptide can win share from two entrenched imports on price alone in a market where prescriptions for the two rivals more than doubled year over year.
The development matters to the peptide therapy and research peptide industry because it marks a new entrant in GLP-1 peptide manufacturing and commercialization outside the United States and Europe, and because Korea’s decision on whether to fold GLP-1 drugs into a managed-coverage scheme could reshape how clinics, distributors and compounding-adjacent suppliers price and source these molecules. For clinics and telehealth operators watching GLP-1 economics, Eppe offers a third supply option — but one whose comparative efficacy has not been established in head-to-head trials.
What happened: Eppe’s launch and its pricing position
Hanmi’s efpeglenatide reached selected Korean clinics on Oct. 29, 2025, following approval by the Ministry of Food and Drug Safety as the country’s first homegrown GLP-1 obesity drug, according to reporting by Qazinform. Distributor-level pricing circulating among distributors puts the first four weeks of treatment at 129,800 won ($96.6).
That undercuts both imports on entry cost. Mounjaro’s starter dose is listed at 278,066 won, while Wegovy’s roughly 216,000 won price was introduced in August 2025, when Novo cut its starting dose price by about 40 percent shortly before Mounjaro entered the Korean market. Eppe’s price advantage persists at maintenance: its 10-milligram dose carries a supply price of 299,200 won for four weeks, about 20 percent below Wegovy’s highest dose and less than half the 675,131 won for Mounjaro’s highest dose.
Those figures are supply prices, not patient bills. South Korea’s national health insurance does not cover obesity treatment, leaving clinics and pharmacies to set their own charges above supply prices.
Key numbers: how Eppe compares with Wegovy and Mounjaro
| Measure | Eppe (efpeglenatide) | Wegovy (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|---|
| Starter four-week supply price (won) | 129,800 | ~216,000 | 278,066 |
| Highest-dose four-week supply price (won) | 299,200 (10 mg) | Reference for ~20% discount | 675,131 |
| Reported average weight loss | 9.75% at 40 weeks (interim Phase 3) | 14.9% at 68 weeks | 20.9% at 72 weeks (highest dose) |
| Korean prescriptions, Jan–Aug 2025 (Wegovy + Mounjaro) | 2,789,992, versus 1,222,574 for all of 2025 per HIRA data submitted to Rep. Kim Yoon | ||
The efficacy figures come from separate trials with different durations, participants and designs, and no trial has compared all three drugs directly. As such, they do not establish a ranking of effectiveness.
Why it matters for peptide therapy clinics and the GLP-1 supply chain
For clinic operators and telehealth platforms, Eppe introduces a lower-cost GLP-1 peptide option in a market where patients pay out of pocket. That could ease price sensitivity at the point of prescribing, but it also raises sourcing and counseling questions: clinics must verify product identity, batch documentation and cold-chain handling for any GLP-1 they stock, and must explain to patients that Eppe’s weight-loss data are interim and not directly comparable to the imported rivals.
The broader peptide supply chain is watching closely. GLP-1 drugs are peptide APIs manufactured through complex synthesis and formulation steps, and demand growth in Korea has already been sharp: Wegovy and Mounjaro were prescribed 2,789,992 times from January through August 2025, compared with 1,222,574 for all of 2025, according to Health Insurance Review and Assessment Service data submitted to Rep. Kim Yoon. That kind of volume growth pulls on API capacity, fill-finish capacity for vials and injection pens, and cold-chain logistics — the same infrastructure that peptide therapy clinics and research peptide suppliers depend on.
Industry observers note that price competition among GLP-1 brands can compress margins for distributors and compounders while increasing total volume, a dynamic that rewards suppliers with documented quality systems and batch traceability. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. It was compiled by PeptideSCM reporter David based on a news lead provided by Sarah, business manager at PeptideDDP, combined with publicly available information online, with the original information sourced from PeptideDDP.com.
Research and market context: efficacy, rebound and the Korean pipeline
Eppe’s reported weight-loss results are more modest than those of its imported rivals. Hanmi reported average weight loss of 9.75 percent at 40 weeks in an interim Phase 3 analysis, while Wegovy recorded 14.9 percent at 68 weeks and the highest dose of tirzepatide produced 20.9 percent at 72 weeks. Because the studies differed in duration, participants and design, the comparison is descriptive rather than definitive.
Patient sentiment reflects that gap. A 51-year-old Busan resident, Park Sun-young, told Qazinform she would not rush to switch, citing unverified effect and satisfaction with Mounjaro purchased during trips to Japan. Her hesitation illustrates the confidence Hanmi must build as it enters a market where prescriptions have more than doubled.
Longer-term durability is the industry’s central question. In an extension of Wegovy’s main trial, participants regained about two-thirds of their lost weight within a year of stopping both the drug and the trial’s lifestyle intervention. Hwang Ju-ri, director of public and international affairs at the Korea Biotechnology Industry Organization, told Qazinform that rebound is the biggest side effect to emerge and that the field needs to see one full cycle. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
The competitive field is widening. Celltrion is developing a four-target injection, CT-G32, alongside a separate oral drug acting on several targets, with clinical trial applications planned for the first half of 2027 for the injection and the second half of 2028 for the pill. Ildong Pharmaceutical has completed early human testing of its oral GLP-1 drug, and Hanmi aims to launch a triple-acting injection in 2030.
Regulatory and cross-border pressure
Price differences between Korea and Japan have encouraged cross-border purchasing. Lawmakers say the gap has driven patients abroad, and the Korea Customs Service intercepted illegally imported obesity drugs 5,030 times in the first eight months of 2025, 4.2 times the total for 2025. Health Minister Jeong Eun-kyeong told a parliamentary audit on Oct. 27 that the government would consider bringing GLP-1 drugs into a managed-coverage scheme that controls prices and use.
For clinics and distributors, that regulatory signal matters more than the launch price. If Korea extends coverage or imposes managed pricing, the economics of stocking Eppe versus imports could shift quickly. Some in the industry expect demand to accelerate further if insurance coverage is extended to obesity treatment, Hwang said.
What comes next
Three data points will determine whether Eppe’s price strategy works. First, real-world persistence — whether patients stay on Eppe beyond the discounted first four weeks. Second, the government’s decision on managed coverage for GLP-1 drugs, which would reset the out-of-pocket calculus. Third, the emergence of head-to-head or long-term extension data that clarify efficacy and rebound across molecules.
For peptide industry professionals, the launch is a reminder that GLP-1 competition is no longer confined to two Western manufacturers. Clinics evaluating new GLP-1 supply should confirm regulatory status, batch-level analytical documentation and storage requirements before adding any product to their formulary; research peptides remain for research use only and are not approved treatments. PeptideDDP tracks supplier and logistics developments relevant to this shifting landscape.
FAQ
What is Eppe (efpeglenatide)?
Eppe is Hanmi Pharmaceutical’s efpeglenatide, approved by South Korea’s Ministry of Food and Drug Safety as the country’s first homegrown GLP-1 obesity drug and launched to selected clinics on Oct. 29, 2025.
How much does Eppe cost compared with Wegovy and Mounjaro?
Eppe’s first four weeks carry a supply price of 129,800 won ($96.6), versus 278,066 won for Mounjaro’s starter dose and about 216,000 won for Wegovy. These are supply prices; Korean patients pay out of pocket above them because obesity treatment is not covered by national health insurance.
Is Eppe more effective than Wegovy or Mounjaro?
No direct comparison exists. Hanmi reported 9.75 percent average weight loss at 40 weeks in an interim Phase 3 analysis, while Wegovy recorded 14.9 percent at 68 weeks and the highest tirzepatide dose produced 20.9 percent at 72 weeks in separate trials with different designs.
Will Korea cover GLP-1 obesity drugs?
Health Minister Jeong Eun-kyeong said on Oct. 27 that the government would consider a managed-coverage scheme controlling prices and use. No decision has been announced.